sglt2 inhibitors vs glp-1 agonists receptor and inhibitors: a couple at last? Renal outcomes of SGLT2 inhibitors

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed type 2 diabetes and weight management

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments

Although patients may regain nearly two-thirds of their lost weight on GLP-1 RAs after cessation of the drug 16 , this early positive reinforcement may serve as an incentive to pursue a long-term, multipronged approach to combat obesity

For most eligible patients, GLP-1 medications are considered safe when: Prescribed by a licensed healthcare provider Initiated at appropriate doses Gradually titrated Monitored regularly These medications have undergone large clinical trials and have more than a decade of safety data in diabetes management

Key Players in the GLP-1 Receptor Agonist Market Novo-Nordisk A/S Eli Lilly And Company Sanofi AstraZeneca Pfizer Inc

& Takami, A